1. Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest www.briantempest.com Mumbai August 2014

2. Hale & Tempest Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian is the Editor of the prestigious Journal of Generic Medicines. Previously he has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world from Tokyo to Las Vegas. He is now a Non Executive Director of Religare Capital Markets, Fortis Healthcare, SRL Diagnostics and Glenmark Pharmaceuticals. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com. Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and owner of Hale & Tempest Co Ltd

3. Hale & Tempest External View of India New PM source: International New York Times June 2 2014

4. Hale & Tempest Global Healthcare Spend to 2025 +6% source: Meet Novartis Management June 17 2014

5. Hale & Tempest Pharma Market to2020 source: Evaluate June 1 2014

6. Hale & Tempest USA New Product Pipeline source: Evaluate June 1 2014

7. Hale & Tempest Access to Medicines – 4% for 47% source: WHO June 2014

8. Hale & Tempest Affordability of Simple Medicines source: WHO, 26 June 2014

9. Hale & Tempest Sovaldi (Gilead)- $1k pill costs $11 source: FT July 31 2014

10. Hale & Tempest Unfortunate Comments source: February 2 2014 Bayer

11. Hale & Tempest Emerging Markets Top 10 Pharma Cos source: Fierce Pharma 10 October 2013

12. Hale & Tempest Global Patent Cliff to 2020 source: Evaluate June 1 2014

13. Hale & Tempest US - India Pharma Market Share source: Meet Novartis Management June 17 2014

14. Hale & Tempest Top 22 Generic Companies source: Generics Bulletin 20 June 2014, 5 India, 1 Japan

15. Hale & Tempest Next 22 Generic Companies source: Generics Bulletin 20 June 2014, 8 India, 2 Japan

16. Hale & Tempest Strength of Local Companies source: IMS May 2012

17. Hale & Tempest GDP 2028 $b source: Centre for Economics and Business research 2013

18. Hale & Tempest Teva versus Actavis and Mylan source: Motley Fool Jul 21 2014

19. Hale & Tempest Actavis Value via M&A source: EGA, June 2014

20. Hale & Tempest Shareholder Return from Indian Pharma source: McKinsey, EGA June 2014

21. Hale & Tempest Stada Focus to Russia from Germany source: Generics Bulletin April 4 2014,Stada

22. Hale & Tempest USA Unsustainable Pricing source: Express Scripts, FT July 31 2014

23. Hale & Tempest Falsified Medicines – including thefts source: EGA June 2014, Advice on Implementation of EU Directive 2011/62/EU

24. Hale & Tempest EU Falsified Medicines Directive - Costs source: EGA June 2014

25. Hale & Tempest EU Falsified Medicines Directive source: Aegate EGA June 2014

26. Hale & Tempest EU Falsified Medicines Directive source: Domino, EGA June 2014

27. Hale & Tempest Valeant – “a house of cards” source: FT June 16 2014

28. Hale & Tempest Acquisition, Divestment & Spin Offs in 2014 valued at $220b from 2012 $50b Novartis - divested Blood Diagnostics, Animal Health to Lilly, OTC, Vaccines and gained GSK Oncology Bayer - Bayer Material Sciences likely sale, buying Merck OTC to become 2 nd in OTC Pfizer - Nutrition & Zoetis Animal Health divested but may bid for GSK, acquired Innopharm GSK - divest tail products, drinks brands, oncology brands and acquired vaccines and OTC to become1st Teva - looking for large acquisition Shire - buys ViroPharma, bought by Abbvie Mylan – buying Abbott mature brands Merck - mature brands & animal health for sale GSK & Sanofi - old brands for sale, NEW STRATEGY Valeant - bidding for Allergan Sun - buying Ranbaxy, bought Pharmalucence

29. Hale & Tempest Thank You brian.tempest@clara.co.uk www.briantempest.com